Glycadia, Inc. With a focus on inhibiting excess nonenzymatic glycation of key proteins, Glycadia aims to reduce the burden of blood-borne factors that trigger abnormalities in cell signaling pathways and molecular mediators underlying diabetic nephropathy, retinopathy, and cardiovascular disease. By leveraging recent discoveries about the causal role of circulating glycated proteins in these complications, Glycadia's science is paving the way for groundbreaking treatments.

Despite the availability of newer glucose-lowering agents, the occurrence and progression of these complications persist. Headquartered in Philadelphia, Glycadia is comprised of an esteemed executive team, board of directors, and scientific advisory board. As a brand, Glycadia is committed to revolutionizing diabetes care and making a significant impact on patients' lives.

Contact Glycadia at 1880 John F Kennedy Blvd, Suite 200, Philadelphia, PA 19103, or reach them by phone at (215) 557-8021 or email at info@glycadia. com